Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

Inclusion Criteria: * Prepubertal children with GHD in Tanner stage 1, aged of 3 years and below 17 years; * Impaired HT defined as at least 2.0 standard deviations (SD) below the mean height for chronological age and sex (HT SDS≤-2.0) according to the Chinese 2005 standard； * Diagnosis of GHD confirmed by 2 different GH stimulation tests, defined as a peak GH level of ≤10 ng/mL, determined with a validated assay. Bone age (BA) at least 6 months less than the chronological age； * Baseline IGF-1 level of at least 1.0 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS ≤-1.0)； * Written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is 8 years old or above). Exclusion Criteria: * Children with a body weight below 12 kg； * Prior exposure to recombinant hGH or IGF-1 therapy； * Children with past or present intracranial tumor growth as confirmed by a sellar MRI scan (with contrast dye recommended) at Screening * Children born SGA (birth weight ≤10th percentile for gestational age according to the Chinese reference)； * Children with psychosocial dwarfism； * Children with idiopathic short stature； * Other causes of short stature such as coeliac disease, hypothyroidism, or rickets； * History or presence of malignant disease; any evidence of present tumor growth; * Subjects with diabetes mellitus； * Closed epiphyses； * Major medical conditions and/or presence of contraindication to hGH treatment； * Participation in any other trial of an investigational agent within 3 months prior to Screening.